Skip to content

Depression: all studies

Page 539 of 1,034: studies 5,381 to 5,390 of 10,336, newest first. Back to the depression overview

Research

The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives.

Pharmacology, Biochemistry, and Behavior November 1, 2025 Shadan Rahmani, Rachel Crupi, Anthony L Riley et al.

After many years of stigma and neglect, there is a resurgence of interest in the therapeutic use of psychedelic drugs. Anecdotal and evidence-based reports indicate psychedelics as a possible treatment for depression, anxiety, PTSD, substance abuse, and other disorders resistant to conventional medical interventions. The available data, however, are limited and the use of psychedelic substances...

Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans.

Toxicological sciences : an official journal of the Society of Toxicology November 1, 2025 Naphat Wittayakarn, Yu-Mei Tan, Pattanachai Choomalaiwong et al.

Ayahuasca is a traditional Amazonian brew composed of Psychotria viridis, containing N,N-dimethyltryptamine (DMT), and Banisteriopsis caapi, which includes harmala alkaloids such as harmine. Ayahuasca can produce potent psychoactive effects primarily due to DMT, whose metabolism is inhibited by harmine via monoamine oxidase-A enzymes. This inhibition increases DMT's systemic bioavailability,...

DOI: 10.1093/toxsci/kfaf118 (opens in new tab) Full text (opens in new tab) Ayahuasca Banisteriopsis caapi Psychotria viridis N,N-Dimethyltryptamine +2

The Role of Psilocybin in End-of-Life Care: Evidence, Mechanisms, and Guidelines

Oncology Rehabilitation in Practice November 1, 2025 Mackenzie Unsworth, Mary Lou Galantino, Robert Sandoval

This article aims to provide a brief overview of the evidence and mechanisms for psilocybin use in EOL care. Additionally, this article will provide guidelines for clinicians to assess patient use and integrate psilocybin into their clinical practice with respect to its current legal status.

Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review

BJPsych Open November 1, 2025 Jonathon Marinis, Sarah Clarke, Alexandre A. Guerin et al. 2 citations

Background Psilocybin-assisted psychotherapy (PAP) has gained attention as a promising intervention for conditions including depression, anxiety and post-traumatic stress disorder, but understanding of its side-effects is limited. This review evaluates the quality of side-effects reporting in PAP trials, to guide treatment, policy and research. Aims To assess side-effects reporting quality in...

DOI: 10.1192/bjo.2025.10847 (opens in new tab) Clinical trial Medline Systematic review Alternative medicine +2

Genome-Wide Translatome Analysis Following Low-Dose Ketamine to Reveal Novel Targets for Antidepressant Treatment.

Synapse November 1, 2025 Oliver H Miller, Nils Grabole, Isabelle Wells et al.

Low-dose ketamine is an efficacious antidepressant for treatment-resistant unipolar and bipolar depressed patients. Major depressive disorder patients receiving a single infusion report elevated mood within 2 h, and ketamine's antidepressant effects have been observed as long as 7 days posttreatment. In light of this remarkable observation, efforts have been undertaken to "reverse-translate"...

DOI: 10.1002/syn.70033 (opens in new tab) Full text (opens in new tab) Ketamine antidepressant Molecular mechanisms Vipr2 target discovery Targeted depression treatment

EVALUATING THE EFFECTIVENESS OF MEDITATION AS A THERAPEUTIC TOOL IN PSYCHOLOGY

Third Desk Research Conference October 31, 2025 G. Chullanaga

Meditation practices of Buddhism, specifically, Samatha (calmness) and Vipassana (insight), are becoming popular in the field of mental health and psychotherapy. These archaic procedures are being brought into the present modes of therapeutic intervention such as cognitive-behavioural therapy (CBT), mindfulness-based stress-reduction (MBSR) and even psychodynamic therapy. The given literature...

PSYCHEDELICS AND ENTACTOGENS IN PSYCHIATRY: PHARMACOLOGY, CLINICAL TRIAL EVIDENCE, AND REGULATORY CONSIDERATIONS

Global Journal of Research in Biology and Pharmacy October 31, 2025 Ifeyinwa Adar Opoku

Psychedelics, including psilocybin, lysergic acid diethylamide, and dimethyltryptamine, and entactogens such as 3,4-methylenedioxymethamphetamine are being investigated for treatment-resistant depression, post-traumatic stress disorder, anxiety, and substance use disorders. These compounds act primarily through serotonin 5-HT2A receptor agonism (psychedelics) or monoamine release (MDMA),...

Meditation a Fast Way to Reduce Fear and Stress

Journal of Clinical Medicine and Regenerative Medicine October 31, 2025 Ven Dr. Sumedh Thero, H. B. Kataria

The meditation claims that it leads to better anti-inflammatory response and healthy aging by proper telomerase regulation. There are also benefits and positives in physical and mental health. The variety of diseases to be studied should be increased. It affects immunology, genetics and various aspects of physical and mental health including depression, substance abuse, eating disorders,...

Ayahuasca prevents the reinstatement of cocaine-induced rewarding effects in C57Bl/6 mice.

Psychopharmacology October 31, 2025 Vítor Bruno, Lídia Emmanuela Wiazowski Spelta, Matheus Lujan Pereira et al.

Ayahuasca is a brew containing the psychedelic compound N,N-dimethyltryptamine (DMT) and β-carbolines, traditionally consumed in indigenous rituals. Recent studies suggest its potential to reduce depression and anxiety and as an alternative for treating ethanol and tobacco use disorders. However, research on its impact on cocaine use disorder remains limited. To analyze the rewarding effects of...

Quercetin protects the myocardium from the effects of ketamine

The Journal of V N Karazin Kharkiv National University series Medicine October 31, 2025 А.о. Mykytenko, V.о. Ponomarenko, V.а. Yakobenchuk et al.

Background. The water soluble form of quercetin, corvitin, may potentially be useful for preventing complications of short-term ketamine analgesia in children and adults, as well as preventing myocardial damage in the treatment of depression and post- traumatic stress disorder. Purpose – was to determine the effect of quercetin on the myocardium of rats under conditions of ketamine-induced...

DOI: 10.26565/2313-6693-2025-56-09 (opens in new tab) Ketamine Peroxynitrite Cardiotoxicity Quercetin +6